Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | October 06, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,108,287 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 50,000 · Balance 6,108,287 F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2023 Filed Oct 5, 2023 22:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $7.29 | $64,777.87 |
DisclosureSEC source: 0001209191-23-052258 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,434,075 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.01 to $7.49 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.36 | $74,277.71 |
DisclosureSEC source: 0001209191-23-050318 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,442,960 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.20 to $8.61 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 23:02 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.79 | $78,136.47 |
DisclosureSEC source: 0001209191-23-048695 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,451,845 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.61 to $9.15 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 21:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.91 | $79,181.34 |
DisclosureSEC source: 0001209191-23-047239 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,460,730 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.70 to $9.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 21:33 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,272 | $11.75 | $38,435.53 |
DisclosureSEC source: 0001209191-23-045330 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,469,615 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.62 to $11.93 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 21:33 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 14,498 | $11.03 | $159,847.70 |
DisclosureSEC source: 0001209191-23-045330 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,472,887 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.62 to $11.60 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,719 | $14.61 | $273,464.00 |
DisclosureSEC source: 0001209191-23-043579 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,487,385 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14.16 to $15.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:54 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $6.89 | $61,193.66 |
DisclosureSEC source: 0001209191-23-042225 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,520,104 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.69 to $7.20 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| June 29, 2023 Filed Jul 27, 2023 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass A Common Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043579 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,506,104 Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 21:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $7.39 | $65,638.83 |
DisclosureSEC source: 0001209191-23-040206 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,528,989 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.19 to $7.575 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy · Derivative | 25,224 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0001209191-23-038847 · doc4.xml · derivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,224 Underlying: Class A Common Stock · 25,224 shares Expires 2033-06-16 F2 · shares: The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 12,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038847 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,537,874 F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 23:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 15,485 | $9.98 | $154,506.23 |
DisclosureSEC source: 0001209191-23-037584 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,525,262 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $9.59 to $10.19 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.79 | $78,133.80 |
DisclosureSEC source: 0001209191-23-033391 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,540,747 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.47 to $9.57 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| May 16, 2023 Filed May 17, 2023 22:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $5.09 | $45,240.64 |
DisclosureSEC source: 0001209191-23-030383 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,549,632 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $4.94 to $5.43 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 21:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $5.93 | $52,729.81 |
DisclosureSEC source: 0001209191-23-025026 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,558,517 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $5.83 to $6.25 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $6.53 | $57,991.51 |
DisclosureSEC source: 0001209191-23-023625 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,567,402 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.43 to $6.84 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 21:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $7.40 | $65,743.67 |
DisclosureSEC source: 0001209191-23-020799 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,576,287 F1 · kind: Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.27 to $7.49 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:36 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.33 | $73,988.95 |
DisclosureSEC source: 0001209191-23-017619 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585,172 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.10 to $8.49 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $7.73 | $68,707.71 |
DisclosureSEC source: 0001209191-23-012321 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,594,057 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.66 to $7.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.81 | $78,262.63 |
DisclosureSEC source: 0001209191-23-008051 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,602,942 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.59 to $9.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 23:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.71 | $77,367.91 |
DisclosureSEC source: 0001209191-23-005098 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,611,827 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.49 to $8.87 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $7.69 | $68,283.00 |
DisclosureSEC source: 0001209191-23-003180 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620,712 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.50 to $7.81 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002066 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,629,597 F1 · shares: Shares were issued in accordance with the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $7.25 | $64,372.71 |
DisclosureSEC source: 0001209191-22-062940 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,628,272 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.13 to $7.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.96 | $79,598.05 |
DisclosureSEC source: 0001209191-22-061487 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,637,157 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.78 to $9.53 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 22:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,885 | $8.75 | $77,785.51 |
DisclosureSEC source: 0001209191-22-059213 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,646,042 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.41 to $8.89 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 17,770 | $11.12 | $197,609.51 |
DisclosureSEC source: 0001209191-22-057958 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,654,927 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.63 to $11.61 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:10 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052909 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,672,697 F1 · shares: Shares were issued in accordance with the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 21:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041273 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,671,777 F1 · shares: Shares were issued in accordance with the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (right to buy) · Derivative | 36,290 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001209191-22-037642 · doc4.xml · derivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,290 Underlying: Class A Common Stock · 36,290 shares Expires 2032-06-14 Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 18,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037642 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,670,591 F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023320 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,652,446 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 01:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 9,625 | $18.03 | $173,528.16 |
DisclosureSEC source: 0001209191-22-002048 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,651,146 F2 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.00 to $18.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002048 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,660,771 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 22:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 9,625 | $18.75 | $180,478.38 |
DisclosureSEC source: 0001209191-21-071103 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,660,216 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.21 to $19.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 400 | $21.03 | $8,411.00 |
DisclosureSEC source: 0001209191-21-068920 · doc4.xml · nonDerivative · entry 3 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,669,841 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.99 to $21.05 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 7,725 | $20.38 | $157,450.95 |
DisclosureSEC source: 0001209191-21-068920 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,670,241 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.98 to $20.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,500 | $19.78 | $29,671.50 |
DisclosureSEC source: 0001209191-21-068920 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,677,966 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.98 to $19.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:20 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 7,725 | $19.05 | $147,193.70 |
DisclosureSEC source: 0001209191-21-066254 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,679,466 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.87 to $19.44 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:20 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,900 | $18.32 | $34,811.42 |
DisclosureSEC source: 0001209191-21-066254 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,687,191 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $17.86 to $18.835 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 00:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059739 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,689,091 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045550 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688,634 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · derivative · entry 7 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Stock · 12,500 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · derivative · entry 6 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries A-1 Preferred Stock · Derivative | 544,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · derivative · entry 5 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 544,743 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries A Preferred Stock · Derivative | 378,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · derivative · entry 4 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 378,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A Preferred Stock into Common Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A Preferred Stock into Common Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A Preferred Stock into Common Stock had no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 7,688,356 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · nonDerivative · entry 3 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 7,688,356 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · nonDerivative · entry 2 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 923,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028026 · doc4.xml · nonDerivative · entry 1 Borgeson Blake · CIK 0001856094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A Preferred Stock into Common Stock had no expiration date. F2 · price: Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.